Basilea Pharmaceutica AG
BPMUFOTCHealthcare● Active
$65.10
$-0.00(-0.00%)
Market Cap$805588844
P/E Ratio—
52W High$74
52W Low$47.5
Basilea Pharmaceutica AG (BPMUF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BPMUF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 17, 2026EPS Actual
$1.95
Est. $2.06 · -5.3%
Revenue
$0.16B
Est. $0.15B · +6.6%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 17, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
BPMUF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | $4.19 | — | — | — | $0.14B | — |
| ▼ Q1 FY2026 | Feb 17, 2026 | $2.06 | $1.95 | -5.3% | $0.16B | $0.15B | +6.6% |
| ▼ Q3 FY2025 | Aug 19, 2025 | $2.56 | $1.44 | -43.8% | $0.13B | $0.12B | +5.7% |
| ▲ Q1 FY2025 | Feb 18, 2025 | $3.57 | $4.52 | +26.6% | $0.15B | $0.14B | +4.1% |
| ▲ Q3 FY2024 | Aug 13, 2024 | $1.30 | $1.67 | +28.5% | $0.09B | $0.12B | -27.9% |
| ▲ Q2 FY2024 | Apr 24, 2024 | -$2.38 | -$2.08 | +12.5% | $0.08B | $0.09B | -0.5% |
| ▲ Q2 FY2023 | Jun 30, 2023 | $0.90 | $2.58 | +187.0% | $0.09B | $0.07B | +30.9% |
| ▲ Q4 FY2022 | Dec 31, 2022 | -$1.41 | $2.20 | +256.5% | $0.10B | $0.05B | +80.4% |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
$4.19
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
$1.95
EPS Est.
$2.06
EPS Surpr.
-5.3%
Revenue
$0.16B
Q3 FY2025
Aug 19, 2025Miss
EPS Actual
$1.44
EPS Est.
$2.56
EPS Surpr.
-43.8%
Revenue
$0.13B
Q1 FY2025
Feb 18, 2025Beat
EPS Actual
$4.52
EPS Est.
$3.57
EPS Surpr.
+26.6%
Revenue
$0.15B
Q3 FY2024
Aug 13, 2024Beat
EPS Actual
$1.67
EPS Est.
$1.30
EPS Surpr.
+28.5%
Revenue
$0.09B
Q2 FY2024
Apr 24, 2024Beat
EPS Actual
-$2.08
EPS Est.
-$2.38
EPS Surpr.
+12.5%
Revenue
$0.08B
Q2 FY2023
Jun 30, 2023Beat
EPS Actual
$2.58
EPS Est.
$0.90
EPS Surpr.
+187.0%
Revenue
$0.09B
Q4 FY2022
Dec 31, 2022Beat
EPS Actual
$2.20
EPS Est.
-$1.41
EPS Surpr.
+256.5%
Revenue
$0.10B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 17, 2026 | -5.3% | $71.00 | $71.00 | +0.00% |
| ▼ Q3 FY2025 | Aug 19, 2025 | -43.8% | $67.75 | $67.75 | +0.00% |
| ▲ Q1 FY2025 | Feb 18, 2025 | +26.6% | $52.83 | $52.83 | +0.00% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +28.5% | $47.00 | $47.00 | +0.00% |
| ▲ Q2 FY2024 | Apr 24, 2024 | +12.5% | $40.75 | $48.15 | +18.16% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +187.0% | $50.00 | $50.00 | +0.00% |
| ▲ Q4 FY2022 | Dec 31, 2022 | +256.5% | $52.00 | $52.00 | +0.00% |
| ▲ Q2 FY2022 | Jun 30, 2022 | +33.6% | $41.00 | $41.00 | +0.00% |
Q1 FY2026+0.00%
Report Date
Feb 17, 2026
EPS Beat/Miss
-5.3%
Price Before
$71.00
Price After
$71.00
Q3 FY2025+0.00%
Report Date
Aug 19, 2025
EPS Beat/Miss
-43.8%
Price Before
$67.75
Price After
$67.75
Q1 FY2025+0.00%
Report Date
Feb 18, 2025
EPS Beat/Miss
+26.6%
Price Before
$52.83
Price After
$52.83
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
+28.5%
Price Before
$47.00
Price After
$47.00
Q2 FY2024+18.16%
Report Date
Apr 24, 2024
EPS Beat/Miss
+12.5%
Price Before
$40.75
Price After
$48.15
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
+187.0%
Price Before
$50.00
Price After
$50.00
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
+256.5%
Price Before
$52.00
Price After
$52.00
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
+33.6%
Price Before
$41.00
Price After
$41.00
Avg Beat Reaction+3.03%
Avg Miss Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move+18.16% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BPMUF ends December
Basilea Pharmaceutica AG (BPMUF) most recently reported earnings on February 17, 2026 for Q1 FY2026, posting EPS of $1.95 — missing the analyst consensus of $2.06 by -5.3%. The next BPMUF earnings date is expected around September 1, 2026.
Each quarter, investors track BPMUF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BPMUF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BPMUF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BPMUF earnings · 5 questionsBasilea Pharmaceutica AG's next earnings report is expected around September 1, 2026. BPMUF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BPMUF historically reports after market close (AMC).
BPMUF earnings datewhen is BPMUF earningsBPMUF next earnings datewhen does BPMUF report earningsBPMUF earnings calendar
▸ Source: FMP · Basilea Pharmaceutica AG SEC filings · US GAAP · Basilea Pharmaceutica AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026